4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Seeking Alpha
The recent Otsuka partnership secures $85M upfront, cost sharing, and milestones, extending FDMT's cash runway into 2028 and supporting global development. 4D-710's early cystic fibrosis data shows promise but lacks clear efficacy in gold-standard endpoints, leaving future prospects uncertain and market reaction muted. Despite multi-billion-dollar market opportunities, current data does not justify a bullish stance; financial risk remains material if pivotal results disappoint. PM Images/DigitalVision via Getty Images Investment Overview - Update Since My Last Note On 4D-150 The last time I updated on the Emeryville, California-based genetic medicine specialist 4D Molecular Therapeutics ( FDMT ) it was early October 2024, and I More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscr
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.MarketBeat
- 4DMT Announces New Employment Inducement GrantsGlobeNewswire
- 4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- 4DMT Provides Company Update and Anticipated Development Milestones for 2026GlobeNewswire
FDMT
Earnings
- 11/10/25 - Beat
FDMT
Sec Filings
- 1/26/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 3
- FDMT's page on the SEC website